Myeloproliferative Neoplasms (MPN): Recent Advances, Current Practices and Future Perspectives
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 82
Special Issue Editor
Interests: nutritional deficiency anaemias; myeloproliferative neoplasms; indolent/low-grade lymphoproliferative disorders; plasma cell dyscrasias
Special Issue Information
Dear Colleagues,
During the last two decades, our understanding of the pathogenesis of Ph-ve chronic myeloproliferative neoplasms.
(MPN: polycythemia vera, essential thrombocythemia and myelofibrosis) has increased significantly. Treatment of patients with MPN has also improved with the introduction of long-acting interferons for cytoreduction and use of JAK-2 inhibitor therapy for symptom relief in patients with myelofibrosis. Risk assessment and prevention of thrombosis have been the focus for several studies. Despite these advances, there are several areas of uncertainty in the management of MPN patients, e.g., dosage schedules for hydroxyurea therapy; indication for the use of aspirin for thromboprophylaxis; dosage schedules for aspirin prophylaxis; choice of JAK-2 inhibitor therapy and the use of cytoreductive therapy in conjunction with JAK-2 inhibitor therapy in patients with myelofibrosis.
The proposed Special Issue aims to record all the recent developments and current management practices, as well as outline possible areas of future research to improve clinical outcomes in patients with MPN.
Suggested Topics:
- Pathogenesis of MPN and diagnosis in the era of molecular studies;
- Risk assessment for thrombosis and initiation of thromboprophylaxis;
- Prognosis and treatment of patients with polycythemia vera;
- Prognosis and treatment of patients with essential thrombocythemia;
- Prognosis and treatment of patients with myelofibrosis;
- Long-term complications in patients with MPN.
Prof. Dr. Arumugam Manoharan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diagnosis
- pathogenesis
- prognosis
- thromboprophylaxis
- treatment
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Translation, Cultural Adaptation and Validation to Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire
Authors: Mihnea-Alexandru Găman; Robyn Marie Scherber; Iulia Ursuleac; Ana Manuela Crisan; Sorina Nicoleta Badelita; Bogdan Octavian Ionescu; Alexandra Elena Ghiaur; Melen Brinza; Nicoleta Pirciulescu; Toma Octavian Lascar; Camelia Cristina Diaconu; Amelia Maria Gaman; Daniel Coriu
Affiliation: . Department of Pathophysiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania
Abstract: Abstract: Background: Patients diagnosed with BCR::ABL1-negative myeloproliferative neoplasms (MPNs) experience a high disease-related symptom burden due to the presence of constitutional symptoms, the occurrence of thrombotic and/or hemorrhagic events, as well as to the propensity of evolution/transformation to secondary myelofibrosis (MF) and/or acute myeloid leukemia. Thus, since individuals living with MPNs display a decreased health-related quality of life (QoL), specific instruments such as the MPN Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS or MPN-10) questionnaire have been developed to evaluate symptom burden and QoL in these he-matological malignancies. Herein, we conducted the translation, cultural adaptation, and valida-tion to Romanian of the MPN-10. Methods: We translated the MPN-10 questionnaire from English to Romanian and tested its psychometric properties in a cohort of 180 Romanian patients suffering from BCR::ABL1-negative MPNs (mean age: 62.75 ± 12.36 years; 54.44% females). Results: We recruited 66 polycythemia vera (PV) (36.67%), 61 essential thrombocythemia (ET) (33.89%), 51 primary (PMF) and secondary MF (SMF) (28.33%) and 2 MPN-unclassifiable (MPNu)(1.11%) subjects. The overall TSS for the entire MPN cohort was 19.51±16.51 points, with higher scores detected in patients with MF versus PV and ET and SMF versus PMF. Overall, our MPN cohort graded fatigue, inactivity, and concentration problems as the most cumbersome symptoms. We detected notable differences between MPN subtypes in terms of individual symptom scores for unintentional weight loss (P
